RÉSUMÉ
Parkinsonism in rats induced by the pesticide rotenone is one of the most adequate models of Parkinson's disease (PD). Isatin (indole-2,3-dione) is an endogenous regulator found in mammals and humans and exhibiting a wide range of biological activities mediated by numerous isatin-binding proteins, including those associated with neurodegenerative pathology. A course of rotenone administration to rats caused behavioral impairments and changes in the profile and relative content of isatin-binding proteins in the brain. In this study, we have investigated the delayed neuroprotective effect of isatin (5 days after completion of the course of rotenone administration) on behavioral reactions and the relative content of isatin-binding proteins in the brain of rats with rotenone-induced experimental parkinsonism. Although during this period the rats retained locomotor dysfunction, the proteomic analysis data (profile of isatin-binding proteins in the brain and changes in their relative content) differed from the results obtained immediately after completion of the course of rotenone administration. Moreover, all isatin-binding proteins with altered relative content changed during this period are associated to varying degrees with neurodegeneration (many with Parkinson's and Alzheimer's diseases).
Sujet(s)
Encéphale , Isatine , Neuroprotecteurs , Roténone , Animaux , Isatine/pharmacologie , Roténone/toxicité , Neuroprotecteurs/pharmacologie , Rats , Mâle , Encéphale/métabolisme , Encéphale/effets des médicaments et des substances chimiques , Encéphale/anatomopathologie , Modèles animaux de maladie humaine , Rat Wistar , Syndrome parkinsonien secondaire/induit chimiquement , Syndrome parkinsonien secondaire/métabolisme , Syndrome parkinsonien secondaire/traitement médicamenteux , Syndrome parkinsonien secondaire/anatomopathologie , Syndromes parkinsoniens/induit chimiquement , Syndromes parkinsoniens/métabolisme , Syndromes parkinsoniens/traitement médicamenteuxRÉSUMÉ
A group of Niclosamide-linked isatin hybrids (Xo, X1, and X2) was created and examined using IR, 1HNMR, 13C NMR, and mass spectrometry. These hybrids' cytotoxicity, antioxidant, cell cycle analysis, and apoptosis-inducing capabilities were identified. Using the SRB assay, their cytotoxicity against the human HCT-116, MCF-7, and HEPG-2 cancer cell lines, as well as VERO (African Green Monkey Kidney), was evaluated. Compound X1 was the most effective compound. In HCT-116 cells, compound X1 produced cell cycle arrest in the G1 phase, promoted cell death, and induced apoptosis through mitochondrial membrane potential breakdown in comparison to niclosamide and the control. Niclosamide and compound X1 reduced reactive oxygen species generation and modulated the gene expression of BAX, Bcl-2, Bcl-xL, and PAR-4 in comparison to the control. Docking modeling indicated their probable binding modalities with the XIAP BIR2 domain, which selectively binds caspase-3/7, and highlighted their structural drivers of activity for further optimization investigations. Computational in silico modeling of the new hybrids revealed that they presented acceptable physicochemical values as well as drug-like characteristics, which may introduce them as drug-like candidates. The study proved that compound X1 might be a novel candidate for the development of anticancer agents as it presents antiproliferative activity mediated by apoptosis.
Sujet(s)
Antinéoplasiques , Antioxydants , Apoptose , Prolifération cellulaire , Isatine , Simulation de docking moléculaire , Niclosamide , Humains , Apoptose/effets des médicaments et des substances chimiques , Isatine/pharmacologie , Isatine/composition chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Antioxydants/pharmacologie , Antioxydants/composition chimique , Animaux , Chlorocebus aethiops , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Cellules Vero , Niclosamide/pharmacologie , Espèces réactives de l'oxygène/métabolisme , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Cellules HCT116 , Lignée cellulaire tumorale , Cellules MCF-7 , Cellules HepG2RÉSUMÉ
Aldehyde dehydrogenases (ALDHs) are a family of enzymes that aid in detoxification and are overexpressed in several different malignancies. There is a correlation between increased expression of ALDH and a poor prognosis, stemness, and resistance to several drugs. Several ALDH inhibitors have been generated due to the crucial role that ALDH plays in cancer stem cells. All of these inhibitors, however, are either ineffective, very toxic, or have yet to be subjected to rigorous testing on their effectiveness. Although various drug-like compounds targeting ALDH have been reported in the literature, none have made it to routine use in the oncology clinic. As a result, new potent, non-toxic, bioavailable, and therapeutically effective ALDH inhibitors are still needed. In this study, we designed and synthesized potent multi-ALDH isoform inhibitors based on the isatin and indazole pharmacophore. Molecular docking studies and enzymatic tests revealed that among all of the synthesized analogs, compound 3 is the most potent inhibitor of ALDH1A1, ALDH3A1, and ALDH1A3, exhibiting 51.32%, 51.87%, and 36.65% inhibition, respectively. The ALDEFLUOR assay further revealed that compound 3 acts as an ALDH broad spectrum inhibitor at 500 nM. Compound 3 was also the most cytotoxic to cancer cells, with an IC50 in the range of 2.1 to 3.8 µM for ovarian, colon, and pancreatic cancer cells, compared to normal and embryonic kidney cells (IC50 7.1 to 8.7 µM). Mechanistically, compound 3 increased ROS activity due to potent multi-ALDH isoform inhibition, which increased apoptosis. Taken together, this study identified a potent multi-isoform ALDH inhibitor that could be further developed as a cancer therapeutic.
Sujet(s)
Aldehyde dehydrogenase , Antienzymes , Isatine , Simulation de docking moléculaire , Humains , Isatine/composition chimique , Isatine/pharmacologie , Aldehyde dehydrogenase/antagonistes et inhibiteurs , Aldehyde dehydrogenase/métabolisme , Antienzymes/composition chimique , Antienzymes/pharmacologie , Antienzymes/synthèse chimique , Lignée cellulaire tumorale , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Relation structure-activité , Isoenzymes/antagonistes et inhibiteurs , Isoenzymes/métabolisme , Structure moléculaireRÉSUMÉ
The use of VEGFR-2 inhibitors as a stand-alone treatment has proven to be ineffective in clinical trials due to the robustness of cellular response loops that lead to treatment resistance when only targeting VEGFR-2. The over-activation of the signal transducer/activator of transcription 3 (STAT-3) is expected to significantly impact treatment failure and resistance to VEGFR-2 inhibitors. In this study, we propose the concept of combined inhibition of VEGFR-2 and STAT-3 to combat induced STAT-3-mediated resistance to VEGFR-2 inhibition therapy. To explore this, we synthesized new isatin-grafted phenyl-1,2,3-triazole derivatives "6a-n" and "9a-f". Screening on PANC1 and PC3 cancer cell lines revealed that compounds 6b, 6 k, 9c, and 9f exhibited sub-micromolar ranges. The most promising molecules, 6b, 6 k, 9c, and 9f, demonstrated the highest inhibition when tested as dual inhibitors on VEGFR-2 (with IC50 range 53-82 nM, respectively) and STAT-3 (with IC50 range 5.63-10.25 nM). In particular, triazole 9f showed the best results towards both targets. Inspired by these findings, we investigated whether 9f has the ability to trigger apoptosis in prostate cancer PC3 cells via the assessment of the expression levels of the apoptotic markers Caspase-8, Bcl-2, Bax, and Caspase-9. Treatment of the PC3 cells with compound 9f significantly inhibited the protein expression levels of VEGFR-2 and STAT-3 kinases compared to the control.
Sujet(s)
Antinéoplasiques , Prolifération cellulaire , Relation dose-effet des médicaments , Conception de médicament , Tests de criblage d'agents antitumoraux , Isatine , Inhibiteurs de protéines kinases , Facteur de transcription STAT-3 , Triazoles , Récepteur-2 au facteur croissance endothéliale vasculaire , Humains , Facteur de transcription STAT-3/antagonistes et inhibiteurs , Facteur de transcription STAT-3/métabolisme , Triazoles/composition chimique , Triazoles/pharmacologie , Triazoles/synthèse chimique , Récepteur-2 au facteur croissance endothéliale vasculaire/antagonistes et inhibiteurs , Récepteur-2 au facteur croissance endothéliale vasculaire/métabolisme , Isatine/pharmacologie , Isatine/composition chimique , Isatine/synthèse chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Relation structure-activité , Structure moléculaire , Inhibiteurs de protéines kinases/pharmacologie , Inhibiteurs de protéines kinases/synthèse chimique , Inhibiteurs de protéines kinases/composition chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Lignée cellulaire tumoraleRÉSUMÉ
The isatin group is widespread in nature and is considered to be a privileged building block for drug discovery. In order to develop novel SHP1 inhibitors with fluorescent properties as tools for SHP1 biology research, this work designed and synthesized a series of isatin derivatives. The presentive compound 5a showed good inhibitory activity against SHP1PTP with IC50 of 11 ± 3 µM, displayed about 92% inhibitory rate against MV-4-11 cell proliferation at the concentration of 20 µM, exhibited suitable fluorescent properties with a long emission wavelength and a large Stokes shift, and presented blue fluorescent imaging in HeLa cells with low cytotoxicity. This study could offer chemical tool to further understand SHP1 biology and develop novel SHP1 inhibitors in therapy.
Sujet(s)
Prolifération cellulaire , Isatine , Isatine/composition chimique , Isatine/pharmacologie , Isatine/synthèse chimique , Humains , Cellules HeLa , Prolifération cellulaire/effets des médicaments et des substances chimiques , Protein Tyrosine Phosphatase, Non-Receptor Type 6/métabolisme , Protein Tyrosine Phosphatase, Non-Receptor Type 6/antagonistes et inhibiteurs , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Relation structure-activité , Structure moléculaire , Colorants fluorescents/composition chimique , Colorants fluorescents/synthèse chimique , Colorants fluorescents/pharmacologie , Lignée cellulaire tumorale , FluorescenceRÉSUMÉ
A new series of isatin-Schiff base linked 1,2,3-triazole hybrids has been synthesized using CuAAC approach from (E)-3-(phenylimino)-1-(prop-2-yn-1-yl)indolin-2-one derivatives in high yield (73-91â %). These synthesized derivatives were characterized using FT-IR, 1H NMR, 13C NMR, 2D-NMR and HRMS spectral techniques. The in vitro antimicrobial activity assay demonstrated that most of the tested hybrids exhibited promising activity. Compoundâ 5 j displayed significant antibacterial efficacy against P. aeruginosa and B. subtilis with MIC value of 0.0062â µmol/mL. While, 5 j also showed better antifungal potency against A. niger with MIC value of 0.0123 µmol/mL. The docking studies of most promising compounds were performed with the well-known antibacterial and antifungal targets i. e. 1KZ1, 5TZ1. Molecular modelling investigations demonstrated that hybrids 5 h and 5 l exhibited good interactions with 1KZN and 5TZ1, with binding energies of -9.6 and -11.0â kcal/mol, respectively. Further, molecular dynamics studies of the compounds showing promising binding interactions were also carried out to study the stability of complexes of these hybrids with both the targets.
Sujet(s)
Antibactériens , Antifongiques , Isatine , Tests de sensibilité microbienne , Bases de Schiff , Triazoles , Bases de Schiff/composition chimique , Bases de Schiff/pharmacologie , Bases de Schiff/synthèse chimique , Isatine/composition chimique , Isatine/pharmacologie , Triazoles/composition chimique , Triazoles/pharmacologie , Triazoles/synthèse chimique , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/synthèse chimique , Antifongiques/pharmacologie , Antifongiques/composition chimique , Antifongiques/synthèse chimique , Aspergillus niger/effets des médicaments et des substances chimiques , Bacillus subtilis/effets des médicaments et des substances chimiques , Simulation de docking moléculaire , Structure moléculaire , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Relation structure-activité , Relation dose-effet des médicamentsRÉSUMÉ
In this study, a series of isatin-chalcone linked triazoles were synthesized using Cu-promoted Azide-Alkyne Cycloaddition (CuAAC) reaction and evaluated for their cytotoxicity against various cancer cell lines. The most potent compound displayed approximately 2.5â times greater activity compared to both reference compounds against ovarian cancer cell lines. These findings were supported by caspase-mediated apoptosis and molecular docking analyses. Docking revealed comparable VEGFR-2 affinities for 5 b and 5-FU but highlighted stronger interaction of 5 b with EGFR, evident from its lower docking score. Overall, these results signify the notable anti-proliferative potential of most synthesized hybrids, notably emphasizing the efficacy of compound 5 b in suppressing cancer cell growth.
Sujet(s)
Antinéoplasiques , Prolifération cellulaire , Conception de médicament , Tests de criblage d'agents antitumoraux , Isatine , Simulation de docking moléculaire , Triazoles , Humains , Triazoles/composition chimique , Triazoles/pharmacologie , Triazoles/synthèse chimique , Isatine/composition chimique , Isatine/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Relation structure-activité , Lignée cellulaire tumorale , Chalcone/composition chimique , Chalcone/pharmacologie , Chalcone/synthèse chimique , Structure moléculaire , Apoptose/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Chalcones/composition chimique , Chalcones/pharmacologie , Chalcones/synthèse chimique , Récepteur-2 au facteur croissance endothéliale vasculaire/antagonistes et inhibiteurs , Récepteur-2 au facteur croissance endothéliale vasculaire/métabolismeRÉSUMÉ
OBJECTIVE: Aim: To evaluate the cytotoxic activity of newly synthesized a series of novel HDAC inhibitors comprising sulfonamide as zinc binding group and Isatin derivatives as cap group joined by mono amide linker as required to act as HDAC inhibitors. PATIENTS AND METHODS: Materials and Methods: The utilization of sulfonamide as zinc binding group joined by N-alkylation reaction with ethyl-bromo hexanoate as linker group that joined by amide reaction with Isatin derivatives as cap groups which known to possess antitumor activity in the designed of new histone deacetylase inhibitors and using the docking and MTT assay to evaluate the compounds. RESULTS: Results: Four compounds have been synthesized and characterized successfully by ART-FTIR, NMR and ESI-Ms. the compounds were synthesized and characterized by successfully by ART-FTIR, NMR and ESI- Ms. Assessed for their cytotoxic activity against human colon adenocarcinoma MCF-7 (IC50, I=105.15, II=60.00, III=54.11, IV=56.57, vorinostat=28.41) and hepatoblastoma HepG2 (IC50, I=63.91, II=135.18, III=118.85, IV=51.46, vorinostat=37.50). Most of them exhibited potent HDAC inhibitory activity and significant cytotoxicity. CONCLUSION: Conclusions: The synthesized compounds (I, II, III and IV) showed cytotoxicity toward MCF-7 and HepG2 cancer cell lines and their docking analysis provided a preliminary indication that they are viable [HDAC6] candidates.
Sujet(s)
Adénocarcinome , Antinéoplasiques , Tumeurs du côlon , Isatine , Humains , Inhibiteurs de désacétylase d'histone/pharmacologie , Inhibiteurs de désacétylase d'histone/composition chimique , Vorinostat/pharmacologie , Isatine/pharmacologie , Lignée cellulaire tumorale , Amides/pharmacologie , Conception de médicament , Antinéoplasiques/pharmacologie , Sulfonamides/pharmacologie , Zinc/métabolisme , Zinc/pharmacologie , Prolifération cellulaire , Structure moléculaireRÉSUMÉ
Multi target directed ligands (MTDLs) are one of the promising tools for treatment of complex disease like Alzheimer's disease (AD). In this study, using rational design, we synthesized new 15 hybrids of the s-triazine, isatin and aniline derivatives as anti- AD compounds. The design was as way as that new compounds could had anti cholinesterase (ChE), antioxidant and biometal chelation ability. In vitro biological evaluation against ChE enzymes showed that these molecules were excellent inhibitors with IC50 values ranging from 0.2 nM to 734.5 nM for acetylcholinesterase (AChE), and 0.02 µM to 1.92 µM for butyrylcholinesterase (BChE). Among these compounds, 8 l with IC50 AChE = 0.7 nM, IC50 BChE = 0.09 µM and 8n with IC50 AChE = 0.2 nM, IC50 BChE = 0.03 µM were the most potent compounds. In silico studies showed that these molecules had key and effective interactions with the corresponding enzymes residues. The molecules with hydroxyl group on aniline moiety had also good antioxidant activity with EC50 values ranging from 64.2 µM to 103.6 µM. The UV-Vis spectroscopy study revealed that molecule 8n was also able to chelate biometals such as Zn2+, Cu2+and Fe2+ properly. It was concluded that these molecules could be excellent lead compounds for future studies.
Sujet(s)
Acetylcholinesterase , Maladie d'Alzheimer , Dérivés de l'aniline , Butyrylcholine esterase , Anticholinestérasiques , Conception de médicament , Isatine , Triazines , Acetylcholinesterase/métabolisme , Maladie d'Alzheimer/traitement médicamenteux , Dérivés de l'aniline/composition chimique , Dérivés de l'aniline/pharmacologie , Dérivés de l'aniline/synthèse chimique , Antioxydants/pharmacologie , Antioxydants/composition chimique , Antioxydants/synthèse chimique , Butyrylcholine esterase/métabolisme , Anticholinestérasiques/pharmacologie , Anticholinestérasiques/composition chimique , Anticholinestérasiques/synthèse chimique , Relation dose-effet des médicaments , Isatine/composition chimique , Isatine/pharmacologie , Isatine/synthèse chimique , Simulation de docking moléculaire , Structure moléculaire , Relation structure-activité , Triazines/composition chimique , Triazines/pharmacologie , Triazines/synthèse chimiqueRÉSUMÉ
Isatin (indoldione-2,3) is an endogenous biological regulator found in the brain, peripheral tissues, and biological fluids of humans and animals. Its biological activity is realized via isatin-binding proteins, many of which were identified during proteomic profiling of the brain of mice and rats. A number of these proteins are related to the development of neurodegenerative diseases. Previously, using a model of experimental Parkinsonism induced by a seven-day course of rotenone injections, we have observed behavioral disturbances, as well as changes in the profile and relative content of brain isatin-binding proteins. In this study, we have investigated behavioral responses and the relative content of brain isatin-binding proteins in rats with rotenone-induced Parkinsonism 5 days after the last administration of this neurotoxin. Despite the elimination of rotenone, animals exhibited motor and coordination impairments. Proteomic profiling of isatin-binding proteins revealed changes in the relative content of 120 proteins (the relative content of 83 proteins increased and that of 37 proteins decreased). Comparison of isatin-binding proteins characterized by the changes in the relative content observed in the brain right after the last injection of rotenone (n=16) and 5 days later (n=11) revealed only two common proteins (glyceraldehyde-3-phosphate dehydrogenase and subunit B of V-type proton ATPase). However, most of these proteins are associated with neurodegeneration, including Parkinson's and Alzheimer's diseases.
Sujet(s)
Isatine , Syndromes parkinsoniens , Humains , Animaux , Rats , Protéines de transport , Isatine/pharmacologie , Roténone/pharmacologie , Protéomique , Encéphale , Syndromes parkinsoniens/induit chimiquementRÉSUMÉ
A new series of isatin-linked benzenesulfonamide derivatives (9a-w) were synthesized using the tail approach and assayed for their inhibitory potency against four different human carbonic anhydrase (hCA) isoforms, hCA I, II, IX, and XII. Most of these synthesized compounds exhibited interesting inhibition potency against isoforms hCA I, IX, and XII in the nanomolar range and by taking the standard drug acetazolamide. The most potent compounds in the case of hCA I were 9c (435.8 nM) and 9s (956.4 nM), for hCA IX, 9a (60.5 nM), 9d (95.6 nM), 9g (92.1 nM), and 9k (75.4 nM), and for hCA XII, 9p (84.5 nM). However, these compounds showed more selectivity toward hCA IX over hCA I, II, and XII. Thus, these compounds can be further developed as potential lead molecules for the development of isoform-selective hCA IX inhibitors with further structural modifications.
Sujet(s)
, Inhibiteurs de l'anhydrase carbonique , Carbonic anhydrases , Conception de médicament , Sulfonamides , Inhibiteurs de l'anhydrase carbonique/pharmacologie , Inhibiteurs de l'anhydrase carbonique/synthèse chimique , Inhibiteurs de l'anhydrase carbonique/composition chimique , Humains , Relation structure-activité , Sulfonamides/pharmacologie , Sulfonamides/synthèse chimique , Sulfonamides/composition chimique , Carbonic anhydrases/métabolisme , Structure moléculaire , Isoenzymes/antagonistes et inhibiteurs , Isoenzymes/métabolisme , Isatine/pharmacologie , Isatine/composition chimique , Isatine/synthèse chimique , Relation dose-effet des médicamentsRÉSUMÉ
The literature reports that thiazole and isatin nuclei present a range of biological activities, with an emphasis on anticancer activity. Therefore, our proposal was to make a series of compounds using the molecular hybridization strategy, which has been used by our research group, producing hybrid molecules containing the thiazole and isatin nuclei. After structural planning and synthesis, the compounds were characterized and evaluated in vitro against breast cancer cell lines (T-47D, MCF-7 and MDA-MB-231) and against normal cells (PBMC). The activity profile on membrane proteins involved in chemoresistance and tumorigenic signaling proteins was also evaluated. Among the compounds tested, the compounds 4c and 4a stood out with IC50 values of 1.23 and 1.39 µM, respectively, against the MDA-MB-231 cell line. Both compounds exhibited IC50 values of 0.45 µM for the MCF-7 cell line. Compounds 4a and 4c significantly decreased P-gp mRNA expression levels in MCF-7, 4 and 2 folds respectively. Regarding the impact on tumorigenic signaling proteins, compound 4a inhibited Akt2 in MDA-MB-231 and compound 4c inhibited the mRNA expression of VIM in MCF-7.
Sujet(s)
Antinéoplasiques , Tumeurs du sein , Isatine , Protéines proto-oncogènes c-akt , ARN messager , Thiazoles , Humains , Protéines proto-oncogènes c-akt/métabolisme , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Tumeurs du sein/traitement médicamenteux , Isatine/pharmacologie , Isatine/composition chimique , Isatine/synthèse chimique , Lignée cellulaire tumorale , ARN messager/métabolisme , ARN messager/génétique , Thiazoles/pharmacologie , Thiazoles/composition chimique , Femelle , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Glycoprotéine P/métabolisme , Glycoprotéine P/génétique , Simulation de docking moléculaire , Cellules MCF-7 , Tests de criblage d'agents antitumoraux , Relation structure-activitéRÉSUMÉ
This article reports one-pot synthesis of ten novel spirooxindoles using 5-methyl-2-thiohydantoin, isatin derivatives, and malononitrile in good to high yields (65-90 %). The structures of the synthesized compounds were deduced by 1H-NMR, 13C NMR, FT-IR, and Mass spectral data. The antibacterial activity of the compounds was evaluated against two Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis) and two Gram-negative bacteria (Escherichia coli and Pseudomonas aeruginosa) based on the Kirby-Bauer method. According to the obtained data, the synthesized compounds show more activity against Gram-positive bacteria than Gram-negative bacteria. Also, the antioxidant activity of these compounds was measured using the DPPH radical scavenging test method, which showed good to excellent activity (59.65-94.03 %). Among them, the chlorinated derivatives (4 f-j) exhibited more antioxidant activity (84.85-94.03 %) than the other compounds (4 a-e) (56.65-74.4 %) and even ascorbic acid as a standard antioxidant compound (82.3 %).
Sujet(s)
Antibactériens , Antioxydants , Indoles , Tests de sensibilité microbienne , Spiranes , Antibactériens/pharmacologie , Antibactériens/synthèse chimique , Antibactériens/composition chimique , Antioxydants/pharmacologie , Antioxydants/synthèse chimique , Antioxydants/composition chimique , Dérivés du biphényle/antagonistes et inhibiteurs , Dérivés du biphényle/composition chimique , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Indoles/composition chimique , Indoles/pharmacologie , Indoles/synthèse chimique , Structure moléculaire , Oxindoles/pharmacologie , Oxindoles/composition chimique , Oxindoles/synthèse chimique , Picrates/antagonistes et inhibiteurs , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Spiranes/composition chimique , Spiranes/pharmacologie , Spiranes/synthèse chimique , , Staphylococcus aureus/effets des médicaments et des substances chimiques , Relation structure-activité , Isatine/synthèse chimique , Isatine/composition chimique , Isatine/pharmacologieRÉSUMÉ
Isatin derivatives have attracted a lot of interest for their potential in the development of new anticancer drugs. A library of 38 isatin derivatives, created through an Ugi four-component reaction, underwent an initial screening in a panel of six human solid tumor cell lines. The four most active derivatives were then selected for further testing. These compounds showed selectivity towards the non-small cell lung cancer (NSCLC) cell line SW1573, whilst NSCLC A549 cells were barely affected. The combination of phenotypic assays, including wound healing, clonogenic and continuous live cell imaging provided a deeper understanding of the compounds' mode of action. In particular, the latter demonstrated that isatin derivatives were able to induce necroptosis in SW1573 cells. The kinetics of cell death showed that necroptosis appeared after 2.5 h of exposure, which could be delayed to 7 h when co-treated with necrostatin-1. Interaction between the isatin derivatives and the KRAS G12C protein variant was discarded after in silico studies. Further studies are warranted to identify the cellular target responsible for the observed selectivity among cell lines.
Sujet(s)
Antinéoplasiques , Carcinome pulmonaire non à petites cellules , Isatine , Tumeurs du poumon , Humains , Cytotoxines , Antinéoplasiques/pharmacologie , Lignée cellulaire tumorale , Isatine/pharmacologie , Tests de criblage d'agents antitumoraux , Relation structure-activité , Prolifération cellulaire , Structure moléculaireRÉSUMÉ
Heterocyclic compounds containing 1,2,3-triazole and isatin as core structures have emerged as promising drug candidates due to their diverse biological activities such as anti-cancer, antifungal, antimicrobial, antitumor, anti-epileptic, antiviral, and more. The presence of 1,2,3-triazoles and isatin heterocycles in these hybrids, both individually known for their medicinal significance, has increasingly piqued the interest of drug discovery researchers, as they seek to delve deeper into their extensive pharmacological potential for enhancing therapeutic efficacy. Moreover, these hybrid compounds are synthetically accessible using readily available materials. Therefore, there is a pressing need to provide a comprehensive overview of the existing knowledge in this field, offering valuable insights to readers and paving the way for the discovery of novel 1,2,3-triazole-linked isatin hybrids with therapeutic potential.
Sujet(s)
Anti-infectieux , Isatine , Tumeurs , Humains , Triazoles/pharmacologie , Triazoles/composition chimique , Relation structure-activité , Isatine/pharmacologie , Isatine/composition chimique , Anti-infectieux/pharmacologieRÉSUMÉ
In this work, a novel isatin-Schiff base L2 had been synthesized through a simple reaction between isatin and 2-amino-5-methylthio-1,3,4-thiadiazole. The produced Schiff base L2 was then subjected to a hydrothermal reaction with cerium chloride to produce the cerium (III)-Schiff base complex C2. Several spectroscopic methods, including mass spectra, FT-IR, elemental analysis, UV-vis, 13C-NMR, 1H-NMR, Thermogravimetric Analysis, HR-TEM, and FE-SEM/EDX, were used to completely characterize the produced L2 and C2. A computer simulation was performed using the MOE software program to find out the probable biological resistance of studied compounds against the proteins in some types of bacteria or fungi. To investigate the interaction between the ligand and its complex, we conducted molecular docking simulations using the molecular operating environment (MOE). The docking simulation findings revealed that the complex displayed greater efficacy and demonstrated a stronger affinity for Avr2 effector protein from the fungal plant pathogen Fusarium oxysporum (code 5OD4) than the original ligand. The antibacterial activity of the ligand and its Ce3+ complex were applied in vitro tests against different microorganism. The study showed that the complex was found to be more effective than the ligand.
Sujet(s)
Cérium , Isatine , Simulation de docking moléculaire , Spectroscopie infrarouge à transformée de Fourier , Isatine/pharmacologie , Isatine/composition chimique , Cérium/pharmacologie , Bases de Schiff/pharmacologie , Bases de Schiff/composition chimique , Simulation numérique , Ligands , Antibactériens/pharmacologie , Tests de sensibilité microbienneRÉSUMÉ
Breast cancer causes a high rate of mortality all over the world. Therefore, the present study focuses on the anticancer activity of new lower rim-functionalized calix[4]arenes integrated with isatin and the p-position of calixarenes with 1,4-dimethylpyridinium iodine against various human cancer cells such as MCF-7 and MDA-MB-231 breast cancer cell lines, as well as the PNT1A healthy epithelial cell line. It was observed that compound 6c had the lowest values in MCF-7 (8.83 µM) and MDA-MB-231 (3.32 µM). Cell imaging and apoptotic activity studies were performed using confocal microscopy and flow cytometry, respectively. The confocal imaging studies with 6c showed that the compound easily entered the cell, and it was observed that 6c accumulated in the mitochondria. The Comet assay test was used to detect DNA damage of compounds in cells. It was found that treated cells had abnormal tail nuclei and damaged DNA structures compared with untreated cells. In vitro human aromatase enzyme inhibition profiles showed that compound 6c had a remarkable inhibitory effect on aromatase. Compound 6c displayed a significant inhibition capacity on aromatase enzyme with the IC50 value of 0.104 ± 0.004 µM. Thus, not only the anticancer activity of the new fluorescent derivatives, which are the subject of this study, but the aromatase inhibitory profiles have also been proven.
Sujet(s)
Antinéoplasiques , Tumeurs du sein , Isatine , Humains , Femelle , Inhibiteurs de l'aromatase/pharmacologie , Antinéoplasiques/composition chimique , Isatine/pharmacologie , Isatine/composition chimique , Aromatase/métabolisme , Relation structure-activité , Lignée cellulaire tumorale , Mitochondries , ADN , Prolifération cellulaire , Tests de criblage d'agents antitumorauxRÉSUMÉ
Sixteen isatin-based hydrazone derivatives (IS1-IS16) were synthesized and assessed for their ability to inhibit monoamine oxidases (MAOs). All the molecules showed improved inhibitory MAO-B activity compared to MAO-A. Compound IS7 most potently inhibited MAO-B with an IC50 value of 0.082 µM, followed by IS13 and IS6 (IC50 = 0.104 and 0.124 µM, respectively). Compound IS15 most potently inhibited MAO-A with an IC50 value of 1.852 µM, followed by IS3 (IC50 = 2.385 µM). Compound IS6 had the highest selectivity index (SI) value of 263.80, followed by IS7 and IS13 (233.85 and 212.57, respectively). In the kinetic study, the Ki values of IS6, IS7, and IS13 for MAO-B were 0.068 ± 0.022, 0.044 ± 0.002, and 0.061 ± 0.001 µM, respectively, and that of IS15 for MAO-A was 1.004 ± 0.171 µM, and the compounds were reversible-type inhibitors. The lead compounds were central nervous system (CNS) permeable, as per parallel artificial membrane permeability assay (PAMPA) test results. The lead compounds were examined for their cytotoxicity and potential neuroprotective benefits in hazardous lipopolysaccharide (LPS)-exposed SH-SY5Y neuroblastoma cells. Pre-treatment with lead compounds enhanced anti-oxidant levels (SOD, CAT, GSH, and GPx) and decreased ROS and pro-inflammatory cytokine (IL-6, TNF-alpha, and NF-kB) production in LPS-intoxicated SH-SY5Y cells. To confirm the promising effects of the compound, molecular docking, dynamics, and MM-GBSA binding energy were used to examine the molecular basis of the IS7-MAO-B interaction. Our findings indicate that lead compounds are potential therapeutic agents to treat neurological illnesses, such as Parkinson's disease.
Sujet(s)
Isatine , Neuroblastome , Neuroprotecteurs , Humains , Inhibiteurs de la monoamine oxydase/pharmacologie , Inhibiteurs de la monoamine oxydase/composition chimique , Isatine/pharmacologie , Neuroprotecteurs/pharmacologie , Simulation de docking moléculaire , Lipopolysaccharides , Relation structure-activité , Monoamine oxidase/métabolisme , Agents colorants/pharmacologieRÉSUMÉ
Tuberculosis (TB) is a global issue that poses a significant economic burden as a result of the ongoing emergence of drug-resistant strains. The urgent requirement for the development of novel antitubercular drugs can be addressed by targeting specific enzymes. One such enzyme, Mycobacterium tuberculosis (MTB) enoyl-acyl carrier protein (enoyl-ACP) reductase (InhA), plays a crucial role in the survival of the MTB bacterium. In this research study, a series of hybrid compounds combining quinolone and isatin were synthesized and assessed for their effectiveness against MTB, as well as their ability to inhibit the activity of the InhA enzyme in this bacterium. Among the compounds tested, 7a and 5g exhibited the most potent inhibitory activity against MTB, with minimum inhibitory concentration (MIC) values of 55 and 62.5 µg/mL, respectively. These compounds were further evaluated for their inhibitory effects on InhA and demonstrated significant activity compared to the reference drug Isoniazid (INH), with IC50 values of 0.35 ± 0.01 and 1.56 ± 0.06 µM, respectively. Molecular docking studies investigated the interactions between compounds 7a and 5g and the target enzyme, revealing hydrophobic contacts with important amino acid residues in the active site. To further confirm the stability of the complexes formed by 5g and 7a with the target enzyme, molecular dynamic simulations were employed, which demonstrated that both compounds 7a and 5g undergo minor structural changes and remain nearly stable throughout the simulated process, as assessed through RMSD, RMSF, and Rg values.
Sujet(s)
Isatine , Mycobacterium tuberculosis , Quinoléines , Humains , Protéine ACP/pharmacologie , Isatine/pharmacologie , Simulation de docking moléculaire , Oxidoreductases/métabolisme , Antituberculeux/pharmacologie , Antituberculeux/composition chimique , Tests de sensibilité microbienne , Quinoléines/pharmacologie , Protéines bactériennes/métabolismeRÉSUMÉ
A catalyst-free synthesis of stable bis-spiropyrrolidines from isatin, secondary amines, and alkylidene Meldrum's acids in MeCN in 75-95% yield is described. The antioxidant and antimicrobial properties of the synthesized compounds are investigated. For this purpose, the radical scavenging activities of four derivatives were studied by radical trapping of diphenylpicrylhydrazine and ferric reduction power experiments. Disk diffusion test on Gram-positive and Gram-negative bacteria was employed to investigate antibacterial activities of five derivatives.